October 21, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Kaneka Confirms Positive Effect of Q10 Against Fatigue
 

Tokyo, Dec 3, 2012 (JCN) - Kaneka Corporation has confirmed the effect of the reduced form coenzyme Q10 (Ubiquinol) in improving the chronic fatigue syndrome showing long-lasting fatigue or tiredness, with unknown cause. This research was conducted in collaboration with Special Appointment Prof. Yasuyoshi Watanabe of Osaka City University Graduate School of Medicine.

Kaneka presented the results at the 7th conference of the International Coenzyme Q10 Association early last month in Seville, Spain.

Twenty patients - consisting of five males and 15 females, with an average age of 36.8 years old - with chronic fatigue syndrome were supplemented with Ubiquinol (150mg/day) for two months. Fatigue, sleep quality and depression, oxidative stress and anti-oxidative activities and arithmetic tasks were evaluated before and after two months of the supplementation.

Based on the results, depression symptoms, sleep duration and the performance in the arithmetic task were improved after the supplementation, and these improvements were dependent on increases in plasma coenzyme Q10 levels - which are correlated with decreases in plasma oxidative stress. It is noteworthy that decreases in oxidative stress and in energy production are related to the mechanism on chronic heart failure syndrome.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Kaneka Corporation News  
  Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
  Kaneka Confirms Positive Effect of Q10 Against Fatigue  (Dec 3, 2012)
  Kaneka and Belgium's imec Develop Next-Generation Heterojunction Solar Cells  (June 14, 2012)
  Kaneka Builds Plant in Malaysia for Production of PI Film  (Apr 21, 2012)
  Kaneka to Establish Umbrella Hubs in Asia and the Americas  (Mar 12, 2012)
  AGC, ADEKA and Kaneka to Withdraw Investments from Kashima Denkai and Kashima PVC Monomer  (Dec 21, 2011)
  Kaneka, MOL and Mitsui Form CPVC JV in India  (Dec 7, 2011)
  Kaneka Develops High-efficiency Heterojunction Silicon Solar Cell  (Nov 28, 2011)
  Kaneka Sets Up Base in South Korea  (Nov 23, 2011)
  Kaneka Trials Production System for 100% Plant Based Biopolymer Product  (May 14, 2011)



 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...

 Recent  Medical News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Medical news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)